New drug to curb hepatitis c

New drug to curb hepatitis c.
The recently approved pharmaceutical Incivek, combined with two timber drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two additional studies show. The poison works not only in patients just starting treatment, but in those who failed earlier treatment, the research found. The hepatitis C virus can hide in the body for years, causing liver damage, cirrhosis and even liver failure doryx java. "This is a significant further in the treatment of hepatitis C," said Dr David Bernstein, supervisor of the division of gastroenterology, hepatology and nutrition at North Shore University Hospital in Manhasset NY, who was not affected in either study.

And "We know that if we can get rid of the hepatitis C, we can stop the progression of liver disease hypercet. This means we can prevent the progression of cirrhosis, we can prevent the development of cancer and also control the need for liver transplantation in a large number of people".

Incivek (telaprevir) was approved by the US Food and Drug Administration in May and is the jiffy drug in a class of drugs called protease inhibitors to be approved to clash hepatitis C The other drug, called Victrelis (boceprevir), was also approved in May. The guide treatment for hepatitis C has been a combination of two drugs, pegylated-interferon and ribavirin, which are given for a year.

If protease inhibitors such as Incivek are added to the mix, the "viral cure" pace improves and the therapy time is reduced to six months, researchers found. Both reports were published in the June 23 online printing of the New England Journal of Medicine.

In one study, a Phase 3 stab known as ADVANCE, patients were randomly assigned to either a placebo or the care in a double-blind study, which means that neither the patients nor the researchers know who's getting the drug and who's getting a made-up treatment. This type of study is considered the gold standard for clinical research.

In the ADVANCE trial, 1088 patients with hepatitis C who had never been treated for the acclimatize were randomly assigned to prevailing therapy for 48 weeks, or telaprevir combined with standard therapy for eight or for 12 weeks, followed by rating therapy alone for a total treatment time of either 24 or 48 weeks. The researchers found that 79 percent of those receiving Incivek for the longest interval (24 weeks) had a "sustained response," which basically means their hepatitis C was contained.